REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-04. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
==== GnRH-associated peptide ==== GnRH-associated peptide (GAP), a 56-amino-acid peptide cleaved from the GnRH precursor, was shown in 1985 to inhibit prolactin secretion in rat pituitary cultures at a potency comparable to dopamine. Its physiological significance in vivo remains uncertain, as results have varied across species.
Eastern Approaches – Fitzroy Maclean's memoir provides his personal experiences in the fledgling SAS in the Western Desert Campaign. Bravo Two Zero – Memoir about a failed SAS mission by Andy McNab. Bravo Two Zero – 1999 miniseries based on the book of the same name by Andy McNab. Red Notice – Novel by Andy McNab, part of his Tom Buckingham Series. SAS: Red Notice – 2021 film based on the book of the same name by Andy McNab. The One That Got Away – Memoir about the Bravo Two Zero mission by Chris Ryan. The One That Got Away – Film based on the book of the same name by Chris Ryan. The Feather Men – Novel by Sir Ranulph Fiennes, claimed by the author to be a partly non-fictional story involving the SAS. Killer Elite – Film based on The Feathermen, about a mercenary hired to kill SAS troopers (fictional story surrounding real events and people from SAS history). 6 Days – Film about the SAS involvement in the Iranian Embassy siege in 1980. Who Dares Wins – 1982 film, released in the United States as The Final Option. SAS: Rogue Heroes – 2016 book. Television shows about the SAS
Mutations in the GSS gene cause glutathione synthetase deficiency. This gene provides instructions for making the enzyme glutathione synthetase. This enzyme is involved in a process called the gamma-glutamyl cycle, which takes place in most of the body's cells. This cycle is necessary for producing a molecule called glutathione. Glutathione protects cells from damage caused by unstable oxygen-containing molecules, which are byproducts of energy production. Glutathione is called an antioxidant because of its role in protecting cells from the damaging effects of these unstable molecules which are byproducts of energy production. Mutations in the GSS gene prevent cells from making adequate levels of glutathione, leading to the signs and symptoms of glutathione synthetase deficiency. This disorder is inherited in an autosomal recessive pattern, which means the defective gene is located on an autosome, and two copies of the gene - one from each parent - are required to be born with the disorder. The parents of an individual with an autosomal recessive disorder each carry one copy of the defective gene, but usually are not affected by the disorder.
==== MeSH E05.337.250 – clinical trials ==== MeSH E05.337.250.200 – clinical trials, phase i MeSH E05.337.250.210 – clinical trials, phase ii MeSH E05.337.250.220 – clinical trials, phase iii MeSH E05.337.250.230 – clinical trials, phase iv MeSH E05.337.250.365 – controlled clinical trials MeSH E05.337.250.365.500 – randomized controlled trials MeSH E05.337.250.500 – multicenter studies
Sources: en.wikipedia.org
=== Pharmacokinetics === Flurpiridaz (18F) has peak blood radioactivity at 2.3 minutes after administration, followed by a rise and plateau. Distribution of this radiopharmaceutical is complex, as it transfuses into the liver (13%), kidneys (9%), brain (8%) and epicardium (3%, radioactivity retains for 1 hour after administration). Full clearance is achieved within 48 hours. Only metabolites of flurpiridaz are excreted, mainly in urine and feces. Flurpiridaz metabolises into many different polar metabolites. There are no differences in pharmacokinetics caused by age, sex, body mass index (BMI), diabetic status, Clid Pugh A hepatic impairment and renal impairment at eGFR≥19-89 mL/min.
John Aylward (November 7, 1946 – May 16, 2022) was an American actor. He was best known for playing the former DNC chairman Barry Goodwin on the NBC television series The West Wing and for playing Dr. Donald Anspaugh on the NBC television series ER. He also provided the voice for Dr. Arne Magnusson in Half-Life 2: Episode Two.
Dried blood spot testing (DBS) is a form of biosampling where blood samples are blotted and dried on filter paper. The dried samples can easily be shipped to an analytical laboratory and analysed using various methods such as DNA amplification or high-performance liquid chromatography.
=== Gas fill === Most modern bulbs are filled with an inert gas to reduce evaporation of the filament and prevent its oxidation. The gas is at a pressure of about 70 kPa (0.7 atm). The gas reduces evaporation of the filament, but the fill must be chosen carefully to avoid introducing significant heat losses. For these properties, chemical inertness and high atomic or molecular weight is desirable. The presence of gas keeps the tungsten below its vapor pressure, allowing it to be operated at higher temperature without reducing its life (or, for operating at the same temperature, prolongs the filament life). On the other hand, the presence of the gas leads to heat loss from the filament—and therefore efficiency loss due to reduced incandescence—by heat conduction and heat convection. Early lamps used only a vacuum to protect the filament from oxygen. The vacuum increases evaporation of the filament but eliminates two modes of heat loss. Some small modern lamps use vacuum as well. The most commonly used fills are:
Materials, which atoms and molecules form constituents in the nanoscale (i.e., they form nanostructures) are called nanomaterials. Nanomaterials are the subject of intense research in the materials science community due to the unique properties that they exhibit. Nanostructure deals with objects and structures that are in the 1 – 100 nm range. In many materials, atoms or molecules agglomerate to form objects at the nanoscale. This causes many interesting electrical, magnetic, optical, and mechanical properties. In describing nanostructures, it is necessary to differentiate between the number of dimensions on the nanoscale. Nanotextured surfaces have one dimension on the nanoscale, i.e., only the thickness of the surface of an object is between 0.1 and 100 nm. Nanotubes have two dimensions on the nanoscale, i.e., the diameter of the tube is between 0.1 and 100 nm; its length could be much greater. Finally, spherical nanoparticles have three dimensions on the nanoscale, i.e., the particle is between 0.1 and 100 nm in each spatial dimension. The terms nanoparticles and ultrafine particles (UFP) often are used synonymously although UFP can reach into the micrometre range. The term 'nanostructure' is often used, when referring to magnetic technology. Nanoscale structure in biology is often called ultrastructure.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.